Want to see VCEL full AI Analyst Report?
VCEL Stock Chart & Stats
$42.44
$0.27(0.60%)
At close: 4:00 PM EDT
$42.44
$0.27(0.60%)
Day’s Range― - ―
52-Week Range$28.95 - $49.32
Previous Close$45
Volume394.66K
Average Volume (3M)487.18K
Market Cap
$2.07B
Enterprise Value$2.26K
Total Cash (Recent Filing)$162.46M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)83.7
Beta0.85
Next Earnings
Nov 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding51,206,615
10 Day Avg. Volume524,772
30 Day Avg. Volume487,182
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$62.67Price Target Upside47.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.55
Revenue Forecast (FY)$336.25M
Bulls Say, Bears Say
Bulls Say
Profitability InflectionThe shift from sustained losses to positive and expanding net margins indicates improved operating leverage and earnings quality. If maintained, stronger profitability can support reinvestment, resilience, and continued commercialization of the product portfolio.
Strong Cash GenerationStrong operating and free cash flow, closely tracking net income, shows that reported earnings are converting into liquidity. This provides internal funding for manufacturing, commercial expansion, and product development while reducing reliance on external capital.
Improving Balance SheetLower leverage and a larger equity base strengthen financial flexibility as the company scales. A more conservative capital structure can help Vericel absorb operating variability and fund durable growth without excessive dependence on debt financing.
Bears Say
Decelerating Revenue GrowthThe marked slowdown in top-line growth could indicate maturing demand, adoption constraints, or a tougher expansion path for existing products. Slower revenue growth may limit operating leverage and make future margin improvement increasingly dependent on cost control.
Free Cash Flow VolatilityAlthough current cash generation is strong, prior negative free cash flow and the recent decline show that conversion can fluctuate. Working-capital needs or reinvestment may periodically absorb liquidity, making funding capacity less predictable during expansion.
Meaningful Debt ObligationsLeverage has improved, but the remaining debt balance still creates fixed financial commitments. If growth moderates or cash conversion weakens, debt service could constrain investment flexibility and slow progress toward a stronger balance sheet.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $28.95 and its highest was $49.32 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $2.07B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Nov 11, 2026 which is in 66 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Jul 30, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.029 by $0.069.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.06.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 51,206,615 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.029. Following the earnings report the stock price went up 2.124%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.67 (47.66% Upside)
$62.67 (47.66% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 24.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vericel Corp
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$62.67
▲(47.66% Upside)
Technical Analysis
Ownership Overview
1.19% Insiders
28.76% Mutual Funds
41.70% Other Institutional Investors
1.88% Public Companies and
Individual Investors